Pharmafile Logo
Pharmafocus logo
Advanced Search

Takeda

Showing 15 posts of 249 posts found.

Von Willebrand disease – increasing awareness and access to vital care

November 4, 2025
Medical Communications, Research and Development European Medicines Association, Haematology, Takeda, Von Willebrand Disease, clinical trials, disease awareness

Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about Von Willebrand disease, its causes …

Feature

Combination treatments: Takeda’s Implementation Framework and the broader landscape

September 23, 2025
Research and Development HIV/AIDS, Hepatology, NHS, NICE, Oncology, Takeda, combination therapy, oncology

Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment landscape and the impact of …

Feature

Takeda presents positive results from trial of chronic kidney disease treatment

June 10, 2025
Research and Development European Renal Association, Immunology, Nephrology, Takeda, autoimmune disease, immunoglobulin A nephropathy (IgAN), kidney disease

Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat patients with primary immunoglobulin A …

News

Takeda announces launch of Framework to help support patient access to life-extending combination treatments

February 25, 2025
Business Services Cancer, HIV/AIDS, Immunology, NHS, NICE, Oncology, Takeda, VPAG, patient access

The Conceptual Implementation Framework outlines critical points within the UK healthcare access ecosystem to help improve the introduction of combination …

News
Press release

Biomarkers used in trial to prevent systematic onset of Crohns Disease before it begins in Europe-first project 

January 22, 2025
Research and Development Crohns Disease, Crohsn, Gastrointestinal tract, Takeda, biomarkers, ibd, project

Takeda, a global biopharmaceutical company, is due to launch a project, INTERCEPT, which will use biomarkers to prevent symptomatic onset …

News

Takeda shares data from phase 3 trial of CIPD treatment

June 20, 2024
Research and Development CIDP, Hyqvia, Neurology, Takeda, clinical trial

Takeda has announced data from the phase 3 ADVANCE-CIDP 3 trial, which assessed the safety and efficacy of Hyqvia (Immune …

News
robina-weermeijer-ihfopazzjhm-unsplash_5

MHRA approves Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy treatment

March 21, 2024
Medical Communications Hyqvia, MHRA, Neurology, Takeda, chronic inflammatory demyelinating polyneuropathy

Takeda has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation to Hyqvia as a …

News

Takeda and ImmunoGen collaborate for development and commercialisation of Elahere in Japan

August 29, 2023
Sales and Marketing Elahere, Immunogen, Oncology, Takeda

ImmunoGen has announced that it has entered into an exclusive collaboration with Takeda Pharmaceutical Company for the development and commercialisation …

News

Takeda and HUTCHMED’s cancer drug shown to prolong overall survival

June 16, 2023
Research and Development HUTCHMED, Oncology, Takeda, colorectal cancer

Clinical trial data from a study into the metastatic colorectal cancer (CRC) drug fruquintinib, which is being developed by Japanese …

News

FDA grants Priority Review for Takeda’s cTTP treatment

May 17, 2023
Research and Development Biologics License Application, Cardiology, FDA, Takeda, cTTP

Japanese biopharmaceutical company Takeda has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application …

News
takeda_wien

Takeda collaboration to optimise biopharmaceutical manufacturing announced

June 22, 2021
Manufacturing and Production Takeda, collaboration, manufacturing

A 36-month joint project between Takeda’s manufacturing site in Vienna, the Research Center Pharmaceutical Engineering (RCPE), InSilicoTrials, and the University …

News
Takeda building

Takeda’s lung cancer drug granted FDA priority review

April 29, 2021
FDA, Takeda, lung cancer treatment, pharma, pharma news

The FDA has granted priority review for Takeda’s New Drug Application (NDA) for its mobocertinib drug for the treatment of …

News
Takeda building

Takeda acquire Maverick in $525m deal to expand cancer therapy portfolio

March 10, 2021
Research and Development Maverick, Takeda, cancer treatment

Takeda has acquired Maverick Therapeutics in a deal worth up to $525 million, in order to expand its portfolio of …

News
Takeda building

Takeda agree $856m deal with Ovid to take over soticlestat development

March 4, 2021
Ovid, Takeda, epilepsy treatment, epiplepsy, soticlestat

Ovid Therapeutics and Takeda have agreed a deal worth up to $856 million, allowing the latter to take over development …

News
takeda_usa_pharmaceuticals_u

Takeda sells four diabetes products to Teijin Pharma for $1.25m

February 26, 2021
Medical Communications Takeda

Takeda has entered into an agreement to transfer the assets, marketing rights, and, eventually, marketing authorisation associated with a portfolio …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025